23andMe (NASDAQ: ME)
23andMe Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
23andMe Company Info
23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. It provides direct access to genetic information with multiple Food and Drug Administration authorizations for genetic health risk reports. The company operates under the Consumer and Research Services segment, and the Therapeutics segment. The firm’s research platform has generated publications on the genetic underpinnings of a range of diseases, conditions, and traits. The platform also powers the 23andMe therapeutics group, pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in South San Francisco, CA.
News & Analysis
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023.
Is 23andMe Stock a Smart Buy Right Now?
It's having trouble getting its core business model to work.
The 3 Worst Stock Investments I Ever Made -- and What I Learned From Them
Not all of my investments have been winners. Here are three that went badly and the important lessons I learned from them.
What Is an Entrepreneur?
Why 23andMe Holding Stock Plummeted by 13% Today
Investors reacted sharply and not well to the company's inaugural set of fiscal 2024 earnings.
Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics
Neither has a traditional business model, but that could be an asset for both.
3 Key Ways That Artificial Intelligence Will Disrupt Biotech Stocks
Biotechs with an AI strategy are likely to be the first to flourish from the disruptions.
AI Revolution on the Horizon: 2 High-Potential Growth Stocks to Watch in 2023
They've been using machine learning for years, and now they might do even more.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.